TCRX TScan Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRX

Price (delayed)

$8.56

Market cap

$409.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.36

Enterprise value

$363.91M

Highlights
TScan Therapeutics's revenue has surged by 56% YoY and by 24% QoQ
TCRX's gross profit has soared by 56% YoY and by 24% from the previous quarter
The equity has soared by 52% YoY but it has contracted by 11% from the previous quarter
The company's net income fell by 35% YoY
TScan Therapeutics's quick ratio has decreased by 9% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of TCRX
Market
Shares outstanding
47.88M
Market cap
$409.87M
Enterprise value
$363.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
26.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.29
Earnings
Revenue
$21.05M
EBIT
-$85.46M
EBITDA
-$80.1M
Free cash flow
-$64.5M
Per share
EPS
-$1.36
Free cash flow per share
-$0.98
Book value per share
$3.15
Revenue per share
$0.32
TBVPS
$4.15
Balance sheet
Total assets
$272.15M
Total liabilities
$121.28M
Debt
$92.43M
Equity
$150.87M
Working capital
$164.42M
Liquidity
Debt to equity
0.61
Current ratio
6.51
Quick ratio
6.61
Net debt/EBITDA
0.57
Margins
EBITDA margin
-380.5%
Gross margin
100%
Net margin
-423.9%
Operating margin
-444%
Efficiency
Return on assets
-33.9%
Return on equity
-60.6%
Return on invested capital
-50.2%
Return on capital employed
-35.3%
Return on sales
-406%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TCRX stock price

How has the TScan Therapeutics stock price performed over time
Intraday
-1.04%
1 week
16.94%
1 month
19.55%
1 year
273.8%
YTD
46.83%
QTD
7.81%

Financial performance

How have TScan Therapeutics's revenue and profit performed over time
Revenue
$21.05M
Gross profit
$21.05M
Operating income
-$93.46M
Net income
-$89.22M
Gross margin
100%
Net margin
-423.9%
TScan Therapeutics's revenue has surged by 56% YoY and by 24% QoQ
TCRX's gross profit has soared by 56% YoY and by 24% from the previous quarter
The company's operating income fell by 40% YoY and by 3% QoQ
The company's net income fell by 35% YoY

Growth

What is TScan Therapeutics's growth rate over time

Valuation

What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
2.71
P/S
26.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.29
The EPS has soared by 51% YoY and by 44% QoQ
The equity has soared by 52% YoY but it has contracted by 11% from the previous quarter
The price to sales (P/S) is 149% higher than the last 4 quarters average of 10.7
TScan Therapeutics's revenue has surged by 56% YoY and by 24% QoQ

Efficiency

How efficient is TScan Therapeutics business performance
TScan Therapeutics's ROIC has soared by 61% YoY and by 7% from the previous quarter
The ROS has increased by 19% QoQ and by 16% YoY
TScan Therapeutics's ROE has decreased by 13% YoY but it has increased by 8% from the previous quarter
The company's return on assets rose by 12% YoY and by 6% QoQ

Dividends

What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRX.

Financial health

How did TScan Therapeutics financials performed over time
The total assets is 124% greater than the total liabilities
The total assets has increased by 37% year-on-year but it has declined by 7% since the previous quarter
The total liabilities has increased by 22% YoY
TScan Therapeutics's debt is 39% lower than its equity
The equity has soared by 52% YoY but it has contracted by 11% from the previous quarter
The debt to equity has declined by 29% year-on-year but it has increased by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.